ライフサイエンスコーパス: endothelin receptor antagonist

1 the current practice of adding bosentan, an endothelin receptor antagonist.

2 ral phosphodiesterase-5 inhibitor or an oral endothelin-receptor antagonist.

3 se biological effects that are unaffected by endothelin receptor antagonists.

4 bitors, niacin, inhaled carbon monoxide, and endothelin receptor antagonists.

5 s of disease-targeted therapy (predominantly endothelin receptor antagonists [47.3%] or phosphodieste

6 -3-methyl-glutaryl-CoA reductase inhibitors, endothelin receptor antagonists and phosphodiesterase ty

7 Conversely, endothelin receptor antagonists and/or KIT blocking anti

8 he treatment of PAH: prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase t

9 Endothelin-receptor antagonists are in clinical use to t

10 ciated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy.

11 hese findings raise the possibility of using endothelin receptor antagonists as neuroprotective agent

12 These data do not support the use of endothelin receptor antagonists as therapy for ILD secon

13 a 12-month trial of bosentan, a nonselective endothelin receptor antagonist, as a therapy for SSc-rel

14 BMS182874, an endothelin receptor antagonist, blocks the effects of ex

15 Treatment with the endothelin receptor antagonist bosentan may be effective

16 liminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercis

17 The endothelin-receptor antagonist bosentan is beneficial in

18 We investigated whether treatment with the endothelin receptor antagonist, bosentan, decreased the

19 The endothelin receptor antagonist BQ-485 (ET(A) selective)

20 Endothelin receptor antagonists (ERA) and phosphodiester

21 Preclinical studies have demonstrated that endothelin receptor antagonists (ERAs) can reduce or pre

22 Oral endothelin receptor antagonists (ERAs) have been shown t

23 Administration of an endothelin receptor antagonist (ETRA, SB 209670) to dogs

24 Atrasentan, an endothelin receptor antagonist, has shown activity in pr

25 Endothelin receptor antagonists have emerged as a novel

26 In cells treated with endothelin receptor antagonists, hydrogen peroxide scave

27 roenvironment and further support the use of endothelin receptor antagonists in the treatment of inva

28 changes of HPS and the effects of selective endothelin receptor antagonists in vivo were assessed af

29 he efficacy and safety of tezosentan, a dual endothelin receptor antagonist, in patients hospitalized

30 nd safety of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with moderat

31 sess the hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with PHT, in

32 Additionally, infusion of endothelin receptor antagonists into the bursa of wild-t

33 The endothelin receptor antagonist is among the most effecti

34 Moreover, endothelin receptor antagonists may have a therapeutic r

35 The vasodilator properties of endothelin receptor antagonists may prove valuable thera

36 Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel

37 us epoprostenol were weaned off post-LT, and endothelin receptor antagonist or phosphodiesterase type

38 y hypoxia but attenuated by either selective endothelin receptor antagonists or oligonucleotides targ

39 were receiving riociguat in combination with endothelin receptor antagonists or prostanoids, or both.

40 hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) pros

41 the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.

42 These effects were prevented by the endothelin receptor antagonist PD145065 (10 microM) and

43 erent classes of drugs are now available-ie, endothelin receptor antagonists, phosphodiesterase-5 inh

44 Administration of a nonselective endothelin receptor antagonist provided essentially equi

45 Although endothelin-receptor antagonists reduce albuminuria in di

46 udy examined the effects of the nonselective endothelin receptor antagonist SB-209,670, and the less

47 The endothelin receptor antagonist tezosentan did not improv

48 Tezosentan is a dual endothelin receptor antagonist that has been shown to im

49 Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemody

50 Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the

51 the efficacy and safety of bosentan, a dual endothelin-receptor antagonist that can be taken orally,

52 mendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong reco

53 We used a specific endothelin receptor antagonist to determine whether ET-1

54 essed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end poin

55 n of the endothelin system with bosentan, an endothelin receptor antagonist, was strongly protective

56 pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study en

57 tment naive or on background therapy with an endothelin receptor antagonist, were eligible.

58 g at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy.